Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
01:11pm, Monday, 08'th Sep 2025
Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary en
2 Beaten-Down Stocks to Buy on the Dip
09:15am, Sunday, 07'th Sep 2025
Investors haven't been kind to Intuitive Surgical (ISRG 2.67%) and Regeneron Pharmaceuticals (REGN 0.96%) this year. Both healthcare leaders have encountered company-specific issues that have led to s
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
04:05pm, Thursday, 04'th Sep 2025
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Confer
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
04:03pm, Thursday, 04'th Sep 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Rela
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
04:46pm, Wednesday, 03'rd Sep 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & St
Michael Burry of Big Short Fame Loves These 3 Stocks
08:54am, Wednesday, 03'rd Sep 2025
I'm a massive fan of Dr. Michael Burry, the man played by Christian Bale in The Big Short, not only because he's made some incredible (albeit high-stakes) calls, even in the years that followed his bi
Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback
06:30pm, Tuesday, 02'nd Sep 2025
Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and lon
Final Trades: ServiceNow, Regeneron, Cisco Systems and Truist Financial
01:34pm, Friday, 29'th Aug 2025
The Investment Committee give you their top stocks to watch for the second half.
Regeneron price target raised to $781 from $753 at Bernstein
06:44am, Wednesday, 27'th Aug 2025
Bernstein raised the firm's price target on Regeneron to $781 from $753 and keeps an Outperform rating on the shares. The firm adds myasthenia gravis to its model following the positive Phase 3 readou
Regeneron's rare immune disorder therapy meets main goal of late-stage trial
07:22am, Tuesday, 26'th Aug 2025
Regeneron Pharmaceuticals said on Tuesday its experimental therapy for treating patients with a rare immune disorder has met the main goal of a late-stage study.
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
07:00am, Tuesday, 26'th Aug 2025
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
08:45am, Sunday, 24'th Aug 2025
Viking Therapeutics (VKTX 1.32%) and Regeneron Pharmaceuticals (REGN -1.45%) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter ha
FDA Extends Review Period of REGN's Submission for Eylea HD
10:56am, Thursday, 21'st Aug 2025
The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
11:19am, Wednesday, 20'th Aug 2025
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
11:11am, Friday, 15'th Aug 2025
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
